Association between Hypocretin-1 and Amyloid-β42 cerebrospinal fluid levels in Alzheimer's disease and healthy controls

Current Alzheimer Research

Volumn 9, Issue 10, 2012, Pages 1119-1125

  Slats, Diane ^a,b   Claassen, Jurgen A H R ^a,b   Lammers, Gert Jan ^c   Melis, René J ^a,b   Verbeek, Marcel M ^a   Overeem, Sebastiaan ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Amyloid ; Cerebrospinal fluid; Circadian rhythms; Hypocretin; Neurobiology; Peptides; Sleep

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; OREXIN A;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; SENILE PLAQUE; SLEEP DISORDER;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CIRCADIAN RHYTHM; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NEUROPEPTIDES; PEPTIDE FRAGMENTS;

EID: 84874899846     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720512804142840     Document Type: Article

References (45)

1. Braak H, Braak E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol 1: 213-16 (1991).
2. Vitiello MV, Prinz PN, Williams DE, Frommlet MS, Ries RK. Sleep disturbances in patients with mild-stage Alzheimer's disease. J Gerontol 45: M131-M38 (1990).
3. McCurry SM, Logsdon RG, Teri L, Gibbons LE, Kukull WA, Bowen JD, et al. Characteristics of sleep disturbance in community-dwelling Alzheimer's disease patients. J Geriatr Psychiatry Neurol Summer 12: 53-9 (1999).
4. Bliwise DL. Sleep disorders in Alzheimer's disease and other dementias. Clin Cornerstone 6(1A):S16-S28 (2004).
5. Bliwise DL, Tinklenberg J, Yesavage JA, Davies H, Pursley AM, Petta DE, et al. REM latency in Alzheimer's disease. Biol Psychiatry 25: 320-28 (1989).
6. Pollak CP, Perlick D. Sleep problems and institutionalization of the elderly. J Geriatr Psychiatry Neurol 4: 204-10 (1991).
7. Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 6: 991-7 (2000).
8. Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 27: 469-74 (2000).
9. de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 95: 322-27 (1998).
10. Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature 437: 1257-63 (2005).
11. Thannickal TC, Lai YY, Siegel JM. Hypocretin (orexin) cell loss in Parkinson's disease. Brain 130: 1586-95 (2007).
12. Ripley B, Overeem S, Fujiki N, Nevsimalova S, Uchino M, Yesavage J, et al. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology 57: 2253-8 (2001).
13. Friedman LF, Zeitzer JM, Lin L, Hoff D, Mignot E, Peskind ER, et al. In Alzheimer disease, increased wake fragmentation found in those with lower hypocretin-1. Neurology 68: 793-94 (2007).
14. Baumann CR, Hersberger M, Bassetti CL. Hypocretin-1 (orexin A) levels are normal in Huntington's disease. J Neurol 253: 1232-33 (2006).
15. Fronczek R, van Geest S, Frolich M, Overeem S, Roelandse FW, Lammers GJ, et al. Hypocretin (orexin) loss in Alzheimer's disease. Neurobiol Aging 33(8):1642-50 (2012).
16. Salomon RM, Ripley B, Kennedy JS, Johnson B, Schmidt D, Zeitzer JM, et al. Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects. Biol Psychiatry 54: 96-104 (2003).
17. Poceta JS, Parsons L, Engelland S, Kripke DF. Circadian rhythm of CSF monoamines and hypocretin-1 in restless legs syndrome and Parkinson's disease. Sleep Med 10: 129-33 (2009).
18. Fronczek R, Overeem S, Lee SY, Hegeman IM, van PJ, van Duinen SG, et al. Hypocretin (orexin) loss in Parkinson's disease. Brain 130: 1577-85 (2007).
19. Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, et al. Amyloid-βbeta dynamics are regulated by orexin and the sleepwake cycle. Science 326: 1005-07 (2009).
20. Wiltfang J, Esselmann H, Bibl M, Hull M, Hampel H, Kessler H, et al. Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with lowand high-CSF A beta 40 load. J Neurochem 101:1053-59 (2007).
21. Slats D, Claassen JA, Spies PE, Borm G, Besse KT, Aalst WV, et al. Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers. Neurobiol Aging 33(4): 831.e1-9 (2012).
22. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-44 (1984).
23. Hatfield CF, Herbert J, Van Someren EJ, Hodges JR, Hastings MH. Disrupted daily activity/rest cycles in relation to daily cortisol rhythms of home-dwelling patients with early Alzheimer's dementia. Brain 127: 1061-74 (2004).
24. Mignot E, Lammers GJ, Ripley B, Okun M, Nevsimalova S, Overeem S, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 59:1553-62 (2002).
25. Johanson CE, Duncan JA, III, Klinge PM, Brinker T, Stopa EG, Silverberg GD. Multiplicity of cerebrospinal fluid functions: New challenges in health and disease. Cerebrospinal.Fluid Res 5:10 (2008).
26. Silverberg GD, Heit G, Huhn S, Jaffe RA, Chang SD, BronteStewart H, et al. The cerebrospinal fluid production rate is reduced in dementia of the Alzheimer's type. Neurology 57: 1763-66 (2001).
27. Grady SP, Nishino S, Czeisler CA, Hepner D, Scammell TE. Diurnal variation in CSF orexin-A in healthy male subjects. Sleep 29: 295-7 (2006).
28. Yoshida Y, Fujiki N, Nakajima T, Ripley B, Matsumura H, Yoneda H, et al. Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. Eur J Neurosci 14: 1075-81 (2001).
29. Zeitzer JM, Buckmaster CL, Parker KJ, Hauck CM, Lyons DM, Mignot E. Circadian and homeostatic regulation of hypocretin in a primate model: implications for the consolidation of wakefulness. J Neurosci 23: 3555-60 (2003).
30. Fujiki N, Yoshida Y, Ripley B, Honda K, Mignot E, Nishino S. Changes in CSF hypocretin-1 (orexin A) levels in rats across 24 hours and in response to food deprivation. Neuroreport 12: 993-97 (2001).
31. Price JL, McKeel DW, Jr., Buckles VD, Roe CM, Xiong C, Grundman M, et al. Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 30: 1026-36 (2009).
32. Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch Neurol 61: 378-84 (2004).
33. Morris JC. Early-stage and preclinical Alzheimer disease. Alzheimer Dis Assoc Disord 19: 163-65 (2005).
34. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 280-92 (2011).
35. Gatfield J, Brisbare-Roch C, Jenck F, Boss C. Orexin receptor antagonists: a new concept in CNS disorders? Chem Med Chem 5:1197-214 (2010).
36. Scammell TE, Matheson JK, Honda M, Thannickal TC, Siegel JM. Coexistence of narcolepsy and Alzheimer's disease. Neurobiol Aging 33(7): 1318-9 (2012).
37. Wang JZ, Wang ZF. Role of melatonin in Alzheimer-like neurodegeneration. Acta Pharmacol Sin 27: 41-49 (2006).
38. Redwine L, Hauger RL, Gillin JC, Irwin M. Effects of sleep and sleep deprivation on interleukin-6, growth hormone, cortisol, and melatonin levels in humans. J Clin Endocrinol Metab 85: 3597-603 (2000).
39. Skene DJ, Vivien-Roels B, Sparks DL, Hunsaker JC, Pevet P, Ravid D, et al. Daily variation in the concentration of melatonin and 5-methoxytryptophol in the human pineal gland: effect of age and Alzheimer's disease. Brain Res 528: 170-4 (1990).
40. Mishima K, Tozawa T, Satoh K, Matsumoto Y, Hishikawa Y, Okawa M. Melatonin secretion rhythm disorders in patients with senile dementia of Alzheimer's type with disturbed sleep-waking. Biol Psychiatry 45: 417-21 (1999).
41. Fronczek R, Overeem S, Lee SY, Hegeman IM, van Pelt J, van Duinen SG, et al. Hypocretin (orexin) loss and sleep disturbances in Parkinson's Disease. Brain 131: e88 (2008).
42. Ferrari E, Arcaini A, Gornati R, Pelanconi L, Cravello L, Fioravanti M, et al. Pineal and pituitary-adrenocortical function in physiological aging and in senile dementia. Exp Gerontol 35:1239-50 (2000).
43. Volicer L, Harper DG, Manning BC, Goldstein R, Satlin A. Sundowning and circadian rhythms in Alzheimer's disease. Am J Psychiatry 158: 704-11 (2001).
44. Sterniczuk R, Dyck RH, Laferla FM, Antle MC. Characterization of the 3xTg-AD mouse model of Alzheimer's disease: part 1. Circadian changes. Brain Res 1348:139-48 (2010).
45. Spies PE, Slats D, Sjogren JM, Kremer BP, Verhey FR, Rikkert MG, et al. The cerebrospinal fluid amyloid beta42/40 ratio in the differentiation of Alzheimer's disease from non-Alzheimer's dementia. Curr Alzheimer Res 7: 470-76 (2010)